NEW YORK, June 1, 2017 /PRNewswire/ --
E-QURE Corp. (OTCQB: EQUR), a Delaware corporation engaged in the commercialization of its Bio-electrical Signal Therapy device (“BST Device”), a new and novel electrotherapy for the non-invasive treatment of hard-to-heal chronic wounds, was issued a new research report.
The research report was published by One Equity Stocks LLC, a leading provider of research on publicly traded emerging growth companies. The research paper can be found at https://www.accesswire.com/464162/Electrical-Stimulation-Therapy-and-E-Qure---A-Potential-20x-in-18-Months-or-Less .
About E-QURE
E-QURE Corp (OTCQB: EQUR) develops, manufactures and markets the E-QURE BST (Bioelectrical Signal Therapy) Device for the treatment and cure chronic wounds such as; pressure ulcers; diabetics foot ulcers; venous stasis ulcers and; hard to heal ulcers. The E-QURE BST device had few regulatory approvals in different part of the world that is currently being renewed. The company is seeking FDA approval for the device to start marketing it in the US.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements, when we discuss the potential of E-QURE BST device to treat wounds. These forward-looking statements and their implications are based on the current expectations of the management of E-QURE only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of E-QURE to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, ADBI undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting E-QURE, reference is made to E-QURE reports filed from time to time with the Securities and Exchange Commission.
Media Contact:
E-QURE Corp
Info@e-qure.com
+972-8-916-7333
SOURCE E-QURE Corp.
